HomeAI · summaries
Storia in 2 fonti
Mounjaro sales dip amid price war as semaglutide generics gain ground
Mounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competitor Novo Nordisk slashing prices on their famed Ozempic and Wegovy, not to mention the influx of cost-effective semaglutide generics. Despite this, Lilly remains optimistic about the distinct advantages Mounjaro brings to its users.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Mounjaro sales dip amid price war as semaglutide generics gain ground
Mounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competitor Novo Nordisk slashing prices on…
- ·
cnbc.com
Eli Lilly slips, Novo Nordisk holds firm as generic weight-loss drugs flood India
Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts to defend Ozempic, Wegovy.